I-SENS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 12:50 am EST
Share
i-SENS, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 67,039.98 million compared to KRW 68,513.87 million a year ago. Net loss was KRW 849.62 million compared to net income of KRW 2,003.19 million a year ago. Basic loss per share from continuing operations was KRW 31 compared to basic earnings per share from continuing operations of KRW 73 a year ago. Diluted loss per share from continuing operations was KRW 31 compared to diluted earnings per share from continuing operations of KRW 73 a year ago. Basic loss per share was KRW 31 compared to basic earnings per share of KRW 73 a year ago.
For the nine months, sales was KRW 807.75 million compared to KRW 2,438.75 million a year ago. Net income was KRW 6,126.21 million compared to KRW 17,420.96 million a year ago. Basic earnings per share from continuing operations was KRW 223 compared to KRW 635 a year ago. Diluted earnings per share from continuing operations was KRW 221 compared to KRW 634 a year ago. Basic earnings per share was KRW 223 compared to KRW 635 a year ago. Diluted earnings per share was KRW 221 compared to KRW 634 a year ago.
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Companyâs products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others; electrolyte analyzers and cartridges; immunosensors, as well as other related accessories, such as connectors, lancets, blood glucose data management software and lancing devices, among others. The Company distributes its products within domestic market and to overseas markets including Japan, Europe, the United States and others.